These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 30989459)

  • 1. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
    Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
    Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
    Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
    Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
    [No Abstract]   [Full Text] [Related]  

  • 3. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
    Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
    Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress.
    Tay KH; Luan Q; Croft A; Jiang CC; Jin L; Zhang XD; Tseng HY
    Cell Signal; 2014 Feb; 26(2):287-94. PubMed ID: 24240056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.
    Croft A; Tay KH; Boyd SC; Guo ST; Jiang CC; Lai F; Tseng HY; Jin L; Rizos H; Hersey P; Zhang XD
    J Invest Dermatol; 2014 Feb; 134(2):488-497. PubMed ID: 23921951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines.
    Hartman ML; Rogut M; Mielczarek-Lewandowska A; Wozniak M; Czyz M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
    Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
    Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
    [No Abstract]   [Full Text] [Related]  

  • 11. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRE1α dissociates with BiP and inhibits ER stress-mediated apoptosis in cartilage development.
    Han X; Zhou J; Zhang P; Song F; Jiang R; Li M; Xia F; Guo FJ
    Cell Signal; 2013 Nov; 25(11):2136-46. PubMed ID: 23816533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ; Le K; Hartsough EJ; Aplin AE
    Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
    Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
    J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
    Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
    Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
    Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
    Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
    Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
    Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.